Study design and ethics
-20
According to the design of general bioequivalence study, due to the long half-life (18-20 days) and immunogenicity characteristics of bevacizumab [Previous studies indicated that the interindividual coefficient of variation (CV) of AUCAll qualified study subjects were admitted to our institution’s Phase I Clinical Research Center on day 1 (prior to administration). They ate a standard meal in the evening and fasted for 10 h before the study. Water intake was restricted from 1 h before the infusion to 1 h after the infusion. According to the prescribing instructions [